Base de dados : MEDLINE
Pesquisa : D20.280.055.500 [Categoria DeCS]
Referências encontradas : 335 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 34 ir para página                         

  1 / 335 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452705
[Au] Autor:Lin L; Chen Z; Cao Y; Sun G
[Ad] Endereço:Department of Otorhinolaryngology-Head and Neck Surgery, Huashan Hospital of Fudan University, Shanghai, China.
[Ti] Título:Normal saline solution nasal-pharyngeal irrigation improves chronic cough associated with allergic rhinitis.
[So] Source:Am J Rhinol Allergy;31(2):96-104, 2017 Mar 01.
[Is] ISSN:1945-8932
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Upper airway inflammation is one of the most commonly identified causes of chronic cough, although the underlying mechanism is not clear. This study compared normal saline solution nasal-pharyngeal irrigation (NSNPI) and fluticasone propionate nasal spray (FPNS) treatment for chronic cough associated with allergic rhinitis (AR). METHODS: Patients with suspected AR to house-dust mite were enrolled, and the symptom of cough was assessed by a cough symptom score and the Leicester Cough Questionnaire, and cough response to capsaicin was evaluated. AR was assessed by using the visual analog scale (VAS) and the Mini Juniper Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ). Mediators, including histamine, leukotriene C4, and prostaglandin D2, and the major basic protein from nasal lavage fluid (NLF) were examined. The patients were treated with NSNPI (the NSNPI group) or FPNS (the FPNS group) for 30 days, after which they were reassessed. RESULTS: Forty-five of 50 patients completed this study. The scores of the cough symptom and the Leicester Cough Questionnaire, and the capsaicin cough threshold all improved statistically after NSNPI but did not change after FPNS. There were statistically significant changes in the evaluations of the MiniRQLQ and the mediators, including histamine and leukotriene C4, in the NLF in the NSNPI group. However, significant changes were found in the assessments of VAS, MiniRQLQ, and all above mediators including histamine, leukotriene C4, and prostaglandin D2, and the major basic protein in the NLF of the FPNS group. Furthermore, the assessments of VAS and all the mediators were reduced more in the FPNS group compared with those in the NSNPI group. CONCLUSION: The patients with suspected AR to house-dust mite reported a better relief of the cough symptom after 30 days of treatment with NSNPI compared with that after nasal corticosteroid.
[Mh] Termos MeSH primário: Tonsila Faríngea/patologia
Tosse/prevenção & controle
Fluticasona/uso terapêutico
Seios Paranasais/patologia
Rinite Alérgica/terapia
Cloreto de Sódio/uso terapêutico
Irrigação Terapêutica
[Mh] Termos MeSH secundário: Tonsila Faríngea/efeitos dos fármacos
Adolescente
Adulto
Idoso
Animais
Antígenos de Dermatophagoides/imunologia
Doença Crônica
Tosse/etiologia
Seres Humanos
Meia-Idade
Sprays Nasais
Seios Paranasais/efeitos dos fármacos
Pyroglyphidae/imunologia
Rinite Alérgica/complicações
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antigens, Dermatophagoides); 0 (Nasal Sprays); 451W47IQ8X (Sodium Chloride); CUT2W21N7U (Fluticasone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.2500/ajra.2017.31.4418


  2 / 335 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29254297
[Au] Autor:Marti J; López F; Gascón I; Julve J
[Ad] Endereço:Pediatric Service Primary Care, La Marina Primary Care Center, Barcelona, Spain.
[Ti] Título:Propolis nasal spray effectively improves recovery from infectious acute rhinitis and common cold symptoms in children: a pilot study.
[So] Source:J Biol Regul Homeost Agents;31(4):943-950, 2017 Oct-Dec.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Currently, treatment for acute rhinitis (AR) is symptomatic but no clear agreement exists to control its development. Propolis extract may appear as a promising natural treatment for AR, but its beneficial effects have not yet been fully tested. Forty children suffering from AR and common cold symptoms aged between 2-12 years were enrolled in a prospective epidemiological multicentre study. A 7-day treatment with propolis nasal spray (3 times/day) was applied and a comparison of symptomatology, subjective global improvement and quality of life (QoL) between baseline (day 1) and final (day 7) visits were performed. The main goal was to evaluate the changes in symptom intensity using the Jackson’s scoring test. After 7 days of treatment there was a significant decrease of symptoms both in the total score (p less than 0.0001) and in regard to each AR symptom (p less than 0.01). On the whole, the sample reported no symptoms by day 7, and the resolution of symptoms occurred approximately at day 4. Furthermore, there was no need for supplementary treatment. Both the subjective global improvement impression and the QoL of patients appeared to significantly improve after treatment. No adverse events (AEs) were found globally. It can be concluded that propolis nasal spray effectively improves recovery from infectious AR and common cold symptoms in children and is an optimal alternative in the treatment of this disease without need for any adjuvant treatment.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Resfriado Comum/tratamento farmacológico
Sprays Nasais
Própole/uso terapêutico
Rinite/tratamento farmacológico
[Mh] Termos MeSH secundário: Doença Aguda
Administração Intranasal
Criança
Pré-Escolar
Resfriado Comum/diagnóstico
Resfriado Comum/fisiopatologia
Feminino
Seres Humanos
Masculino
Projetos Piloto
Estudos Prospectivos
Qualidade de Vida/psicologia
Rinite/diagnóstico
Rinite/fisiopatologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Nasal Sprays); 9009-62-5 (Propolis)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  3 / 335 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28975301
[Au] Autor:Fralick M; Kesselheim AS
[Ad] Endereço:Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School, Boston, Massachusetts.
[Ti] Título:Low-Dose Desmopressin Nasal Spray and FDA Approval-Reply.
[So] Source:JAMA;318(11):1071-1072, 2017 09 19.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Desamino Arginina Vasopressina
Sprays Nasais
[Mh] Termos MeSH secundário: Administração Intranasal
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Nasal Sprays); ENR1LLB0FP (Deamino Arginine Vasopressin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171011
[Lr] Data última revisão:
171011
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.11343


  4 / 335 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28975296
[Au] Autor:Fein S; Herschkowitz S
[Ad] Endereço:Serenity Pharmaceuticals, Milford, Pennsylvania.
[Ti] Título:Low-Dose Desmopressin Nasal Spray and FDA Approval.
[So] Source:JAMA;318(11):1070-1071, 2017 09 19.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Desamino Arginina Vasopressina
Sprays Nasais
[Mh] Termos MeSH secundário: Administração Intranasal
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Nasal Sprays); ENR1LLB0FP (Deamino Arginine Vasopressin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171011
[Lr] Data última revisão:
171011
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.11327


  5 / 335 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28802371
[Au] Autor:Ocak E; Kocaoz D; Acar B
[Ad] Endereço:Department of Otorhinolaryngology, Kecioren Research and Training Hospital, Ankara, Turkey.
[Ti] Título:How can we improve medical adherence to intranasal corticosteroids in children?
[So] Source:Int J Pediatr Otorhinolaryngol;100:194-197, 2017 Sep.
[Is] ISSN:1872-8464
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To evaluate the factors which may be related to nonadherence to intranasal corticosteroids (ICS) in the treatment of allergic rhinitis (AR) in children. METHODS: A prospective study was conducted on children with AR diagnosis in a tertiary referral hospital. All participants were provided with mometasone furoate nasal sprays for 30 days after the diagnosis. Caregivers were called back when the therapy was over and completed a questionnaire about the factors that may influence the adherence to the treatment. Afterwards each caregiver completed the Turkish language validated Morisky Medical Adherence Scale (MMAS-8) form. Each factor was evaluated according to MMAS-8 score and all variables were analyzed statistically. RESULTS: A total number of 76 children with a mean age of 7.82 years were included in the study. The mean overall MMAS-8 score was 2.80. There was only one factor significantly related to low adherence; the number of dependent children to the caregiver (p = 0.011). Besides this 71.51% of the answers to MMAS-8 scale were compatible with good adherence. CONCLUSION: The clinician must consider the factors which may lead to non-adherence while setting up a treatment plan. The demographic and sociocultural factors must be taken into consideration and treatment schedule should be made in respect of daily activities of the children. Moreover the father can be involved in the therapy plan and back up the mother as they are usually the responsible parent for children's medical therapy.
[Mh] Termos MeSH primário: Antialérgicos/administração & dosagem
Glucocorticoides/administração & dosagem
Adesão à Medicação
Furoato de Mometasona/administração & dosagem
Rinite Alérgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Intranasal
Criança
Feminino
Seres Humanos
Masculino
Sprays Nasais
Estudos Prospectivos
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Glucocorticoids); 0 (Nasal Sprays); 04201GDN4R (Mometasone Furoate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170814
[St] Status:MEDLINE


  6 / 335 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28766959
[Au] Autor:Beswick DM; Messner AH; Hwang PH
[Ad] Endereço:1 Stanford University School of Medicine, Department of Otolaryngology-Head and Neck Surgery, Stanford, California, USA.
[Ti] Título:Pediatric Chronic Rhinosinusitis Management in Rhinologists and Pediatric Otolaryngologists.
[So] Source:Ann Otol Rhinol Laryngol;126(9):634-639, 2017 Sep.
[Is] ISSN:1943-572X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare the management of pediatric chronic rhinosinusitis (PCRS) between members of the American Rhinologic Society (ARS) and the American Society of Pediatric Otolaryngology (ASPO). STUDY DESIGN: Comparison of surveys. METHODS: A web-based survey was distributed to ASPO membership twice in September-October 2016. Data were compared to previously published data from ARS membership in March-April 2016. RESULTS: ASPO survey completion rate was 22%. ARS members were more likely to employ oral steroids in initial ( P = .025) and maximal medical management ( P = .001). ASPO members more commonly performed adenoidectomy before computed tomography (CT) ( P < .001). Both groups commonly included adenoidectomy as part of initial surgical management (90% vs 94%, P = .316), while ASPO members more frequently performed adenoidectomy alone (70% vs 43%, P = .001). If initial surgical treatment failed, both groups commonly performed endoscopic sinus surgery (ESS; 81% vs 88%, P = .56) with a similar extent including frontal ( P ≥ .207) and sphenoid ( P ≥ .304) surgery. CONCLUSIONS: Pediatric chronic rhinosinusitis management is similar between groups, yet there are differences including oral steroid use, relative order of CT versus adenoidectomy, and performing concomitant procedures with adenoidectomy. Both groups commonly perform ESS with similar surgical extent if prior surgical treatment fails. Management by both groups is largely in agreement with published consensus statements.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Glucocorticoides/uso terapêutico
Antagonistas dos Receptores Histamínicos/uso terapêutico
Otorrinolaringologistas
Procedimentos Cirúrgicos Otorrinolaringológicos/métodos
Pediatras
Rinite/terapia
Sinusite/terapia
[Mh] Termos MeSH secundário: Adenoidectomia/métodos
Adenoidectomia/utilização
Administração Oral
Criança
Doença Crônica
Gerenciamento Clínico
Endoscopia
Seres Humanos
Sprays Nasais
Otolaringologia
Procedimentos Cirúrgicos Otorrinolaringológicos/utilização
Pediatria
Guias de Prática Clínica como Assunto
Padrões de Prática Médica
Rinite/diagnóstico por imagem
Sinusite/diagnóstico por imagem
Sociedades Médicas
Inquéritos e Questionários
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Glucocorticoids); 0 (Histamine Antagonists); 0 (Nasal Sprays)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE
[do] DOI:10.1177/0003489417719717


  7 / 335 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28587510
[Au] Autor:Spadijer Mirkovic C; Peric A; Vukomanovic Durdevic B; Vojvodic D
[Ad] Endereço:1 Department of Otorhinolaryngology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.
[Ti] Título:Effects of Fluticasone Furoate Nasal Spray on Parameters of Eosinophilic Inflammation in Patients With Nasal Polyposis and Perennial Allergic Rhinitis.
[So] Source:Ann Otol Rhinol Laryngol;126(8):573-580, 2017 Aug.
[Is] ISSN:1943-572X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Regulated on activation normal T cell expressed and secreted (RANTES) and eotaxin-2 have been postulated to be responsible for eosinophilia in chronically inflamed nasal mucosa. This study evaluated mucosal production of RANTES and eotaxin-2 in patients with perennial allergic rhinitis (PAR) and nonallergic and allergic form of chronic rhinosinusitis with nasal polyps (CRSwNP) before and after nasal corticosteroid treatment. METHODS: Twenty patients with PAR, 20 nonallergic and 20 allergic CRSwNP patients, and 20 healthy controls were included. The RANTES and eotaxin-2 levels were measured in nasal secretion samples. The patients with chronic inflammation were treated with fluticasone furoate nasal spray for 2 weeks. Cytological examination and measurement of RANTES and eotaxin-2 in nasal fluid were performed before and after the treatment. RESULTS: The levels of RANTES were higher in patients with PAR ( P < .05) and nonallergic ( P < .01) and allergic CRSwNP patients ( P < .001) compared to controls. Eotaxin-2 levels were higher in all 3 inflammation groups compared to healthy subjects ( P < .001). After the treatment, we found a significant decrease of RANTES and eotaxin-2 concentrations ( P < .001) in all 3 groups of patients. CONCLUSION: The levels of RANTES and eotaxin-2 in nasal fluid could be reliable markers for assessing corticosteroid administration outcomes.
[Mh] Termos MeSH primário: Androstadienos/uso terapêutico
Glucocorticoides/uso terapêutico
Pólipos Nasais/tratamento farmacológico
Rinite Alérgica/tratamento farmacológico
Rinite/tratamento farmacológico
Sinusite/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Estudos de Casos e Controles
Quimiocina CCL24/metabolismo
Quimiocina CCL5/metabolismo
Doença Crônica
Ensaio de Imunoadsorção Enzimática
Eosinofilia/tratamento farmacológico
Eosinofilia/metabolismo
Feminino
Seres Humanos
Inflamação
Masculino
Meia-Idade
Mucosa Nasal/metabolismo
Pólipos Nasais/metabolismo
Sprays Nasais
Rinite/metabolismo
Rinite Alérgica/metabolismo
Sinusite/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androstadienes); 0 (CCL24 protein, human); 0 (CCL5 protein, human); 0 (Chemokine CCL24); 0 (Chemokine CCL5); 0 (Glucocorticoids); 0 (Nasal Sprays); JS86977WNV (fluticasone furoate)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170821
[Lr] Data última revisão:
170821
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE
[do] DOI:10.1177/0003489417713505


  8 / 335 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28581833
[Au] Autor:Young PM; Traini D; Ong HX; Granieri A; Zhu B; Scalia S; Song J; Spicer PT
[Ad] Endereço:a Respiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, School of Medicine , University of Sydney , Glebe , New South Wales , Australia.
[Ti] Título:Novel nano-cellulose excipient for generating non-Newtonian droplets for targeted nasal drug delivery.
[So] Source:Drug Dev Ind Pharm;43(10):1729-1733, 2017 Oct.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Thickening polymers have been used as excipients in nasal formulations to avoid nasal run-off (nasal drip) post-administration. However, increasing the viscosity of the formulation can have a negative impact on the quality of the aerosols generated. Therefore, the study aims to investigate the use of a novel smart nano-cellulose excipient to generate suitable droplets for nasal drug delivery that simultaneously has only marginally increased viscosity while still reducing nasal drips. METHODS: Nasal sprays containing nano-cellulose at different concentrations were investigated for the additive's potential as an excipient. The formulations were characterized for their rheological and aerosol properties. This was then compared to conventional nasal spray formulation containing the single-component hydroxyl-propyl methyl cellulose (HPMC) viscosity enhancing excipient. RESULTS: The HPMC-containing nasal formulations behave in a Newtonian manner while the nano-cellulose formulations have a yield stress and shear-thinning properties. At higher excipient concentrations and shear rates, the nano-cellulose solutions have significantly lower viscosities compared to the HPMC solution, resulting in improved droplet formation when actuated through conventional nasal spray. CONCLUSIONS: Nano-cellulose materials could potentially be used as a suitable excipient for nasal drug delivery, producing consistent aerosol droplet size, and enhanced residence time within the nasal cavity with reduced run-offs compared to conventional polymer thickeners.
[Mh] Termos MeSH primário: Aerossóis/química
Celulose/química
Sistemas de Liberação de Medicamentos/métodos
Excipientes/química
Polímeros/química
Reologia/métodos
[Mh] Termos MeSH secundário: Aerossóis/administração & dosagem
Química Farmacêutica
Sprays Nasais
Viscosidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Excipients); 0 (Nasal Sprays); 0 (Polymers); 9004-34-6 (Cellulose)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1339078


  9 / 335 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28251391
[Au] Autor:Munjal S; Brand-Schieber E; Allenby K; Spierings ELH; Cady RK; Rapoport AM
[Ad] Endereço:Dr. Reddy's Laboratories Ltd., 107 College Road East Princeton, Princeton, NJ, 08540, USA. smunjal@drreddys.com.
[Ti] Título:A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.
[So] Source:J Headache Pain;18(1):31, 2017 Dec.
[Is] ISSN:1129-2377
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: DFN-02 is a novel intranasal spray formulation composed of sumatriptan 10 mg and a permeation-enhancing excipient comprised of 0.2% 1-O-n-Dodecyl-ß-D-Maltopyranoside (DDM). This composition of DFN-02 allows sumatriptan to be rapidly absorbed into the systemic circulation and exhibit pharmacokinetics comparable to subcutaneously administered sumatriptan. Rapid rate of absorption is suggested to be important for optimal efficacy. The objective of this study was to evaluate the safety and tolerability of DFN-02 (10 mg) in the acute treatment of episodic migraine with and without aura over a 6-month period based on the incidence of treatment-emergent adverse events and the evaluation of results of clinical laboratory tests, vital signs, physical examination, and electrocardiograms. METHODS: This was a multi-center, open-label, repeat-dose safety study in adults with episodic migraine with and without aura. Subjects diagnosed with migraine with or without aura according to the criteria set forth in the International Classification of Headache Disorders, 2nd edition, who experienced 2 to 6 attacks per month with fewer than 15 headache days per month and at least 48 headache-free hours between attacks, used DFN-02 to treat their migraine attacks acutely over the course of 6 months. RESULTS: A total of 173 subjects was enrolled, 167 (96.5%) subjects used at least 1 dose of study medication and were evaluable for safety, and 134 (77.5%) subjects completed the 6-month study. A total of 2211 migraine attacks was reported, and 3292 doses of DFN-02 were administered; mean per subject monthly use of DFN-02 was 3.6 doses. Adverse events were those expected for triptans, as well as for nasally administered compounds. No new safety signals emerged. Dysgeusia and application site pain were the most commonly reported treatment-emergent adverse events over 6 months (21% and 30.5%, respectively). Most of the treatment-emergent adverse events were mild. There were 5 serious adverse events, all considered unrelated to the study medication; the early discontinuation rate was 22.5% over the 6-month treatment period. CONCLUSION: DFN-02 was shown to be well tolerated when used over 6 months to treat episodic migraine acutely.
[Mh] Termos MeSH primário: Maltose/análogos & derivados
Transtornos de Enxaqueca/tratamento farmacológico
Sumatriptana/efeitos adversos
Vasoconstritores/efeitos adversos
[Mh] Termos MeSH secundário: Administração Intranasal
Adulto
Combinação de Medicamentos
Feminino
Seres Humanos
Masculino
Maltose/administração & dosagem
Maltose/efeitos adversos
Maltose/farmacologia
Meia-Idade
Sprays Nasais
Sumatriptana/administração & dosagem
Sumatriptana/farmacologia
Resultado do Tratamento
Vasoconstritores/administração & dosagem
Vasoconstritores/farmacologia
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Nasal Sprays); 0 (Vasoconstrictor Agents); 0 (dodecyl maltopyranoside); 69-79-4 (Maltose); 8R78F6L9VO (Sumatriptan)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170510
[Lr] Data última revisão:
170510
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE
[do] DOI:10.1186/s10194-017-0740-3


  10 / 335 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28249059
[Au] Autor:Leventhal WD
[Ad] Endereço:Summerville, SC, USA.
[Ti] Título:An overlooked Rx for nasal obstruction relief.
[So] Source:J Fam Pract;66(3):135, 2017 Mar.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We frequently recommend ipratropium nasal spray in our office, as it is an effective, non-addictive nasal decongestant.
[Mh] Termos MeSH primário: Ipratrópio/administração & dosagem
Obstrução Nasal/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
Descongestionantes Nasais/administração & dosagem
Sprays Nasais
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Nasal Decongestants); 0 (Nasal Sprays); GR88G0I6UL (Ipratropium)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE



página 1 de 34 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde